Y-Intercept (HK)’s Sarepta Therapeutics SRPT Stock Holding History

Y-Intercept (HK)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16M	Buy	231,501 +142,557	+160%	+$2.7M	0.08%	341
2026 Q1	$1.94M	Buy	+88,944	New	+$1.72M	0.04%	732
2025 Q4	–	Sell	-78,735	Closed	-$1.52M	–	1965
2025 Q3	$1.52M	Sell	78,735 -791,446	-91%	-$14.1M	0.04%	771
2025 Q2	$14.9M	Buy	870,181 +822,799	+1,737%	+$35.1M	0.36%	25
2025 Q1	$3.02M	Buy	47,382 +38,292	+421%	+$4.03M	0.2%	108
2024 Q4	$1.11M	Buy	9,090 +1,143	+14%	+$140K	0.07%	389
2024 Q3	$993K	Sell	7,947 -29,809	-79%	-$4.12M	0.06%	452
2024 Q2	$5.97M	Buy	37,756 +28,568	+311%	+$3.67M	0.33%	49
2024 Q1	$1.19M	Buy	+9,188	New	+$1.13M	0.09%	319
2023 Q2	–	Sell	-13,926	Closed	-$1.92M	–	1703
2023 Q1	$1.92M	Sell	13,926 -2,567	-16%	-$333K	0.22%	94
2022 Q4	$2.14M	Buy	+16,493	New	+$1.91M	0.32%	48
2022 Q3	–	Sell	-9,962	Closed	-$747K	–	1252
2022 Q2	$747K	Buy	9,962 +5,917	+146%	+$435K	0.1%	303
2022 Q1	$316K	Sell	4,045 -4,056	-50%	-$311K	0.07%	428
2021 Q4	$729K	Sell	8,101 -597	-7%	-$51K	0.17%	172
2021 Q3	$804K	Buy	+8,698	New	+$670K	0.15%	224
2021 Q2	–	Sell	-6,585	Closed	-$481K	–	881
2021 Q1	$481K	Buy	6,585 +2,495	+61%	+$230K	0.13%	265
2020 Q4	$702K	Buy	+4,090	New	+$606K	0.3%	86

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Y-Intercept (HK)'s SRPT Position: Q2 2026 in Review

Y-Intercept (HK) increased its Sarepta Therapeutics (SRPT) stake by 160% in Q2 2026, buying an estimated $2.7M and bringing the position to 231,501 shares worth $4.16M. The position accounts for 0.08% of the portfolio, ranked #341.

Y-Intercept (HK) first reported a position in SRPT in Q4 2020 and has held it in 17 quarters since. The position peaked at $14.9M in Q2 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Y-Intercept (HK) held 231,501 shares of Sarepta Therapeutics worth $4.16M as of Q2 2026.
Y-Intercept (HK) bought 142,557 Sarepta Therapeutics shares in Q2 2026, an estimated $2.7M.
Sarepta Therapeutics made up 0.08% of Y-Intercept (HK)'s portfolio in Q2 2026, its #341 holding.
Y-Intercept (HK) first reported a position in Sarepta Therapeutics in Q4 2020 and has held it in 17 quarters since.
Y-Intercept (HK)'s Sarepta Therapeutics position peaked at $14.9M in Q2 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.